LLY Eli Lilly and Company

Mentions (100)

• Newsbarrons.com·21h ago·Negative

  Lilly Expands Oncology Footprint With FDA Win for Pancreatic Cancer Drug Eli Lilly's experimental cancer treatment, olomorasib, receives orphan drug designation from the Food and Drug Administration.

  View source ↗
• Newszacks.com·22h ago·Neutral

  FDA Expands Eli Lilly's Blood Cancer Drug Label in First-Line Setting LLY's Jaypirca gains FDA approval for first-line CLL/SLL, with strong trial results and rising sales bolstering its cancer portfolio.

  View source ↗
• Newsprnewswire.com·1d ago·Negative

  … (tirzepatide) vs. Taltz alone in the TOGETHER-PsO study in adults with psoriasis and obesity INDIANAPOLIS, Oct. 5, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will present new data across its dermatology portfolio at the 2026 Fall Clinical Dermatology Conference taking place Oct. 8-11 in Las Vegas.

  View source ↗
• Newsfool.com·2d ago·Negative

  Forget Zepbound: Eli Lilly's Next Weight-Loss Drug Could Be Its Biggest Blockbuster Yet Eli Lilly's next-gen anti-obesity medicine has posted highly encouraging clinical trial results. The company boasts several other pipeline candidates in this area.

  View source ↗
• Newsfool.com·2d ago·Negative

  Eli Lilly Just Announced Something Big. Here's What It Means for Investors. Eli Lilly dominates the weight loss drug market, one that's on track to approach $100 billion in just a few years. The company's current weight loss drugs generated $14 billion in sales in the recent quarter.

  View source ↗
• Newsprnewswire.com·3d ago·Negative

  …ives expanded indication from U.S. FDA for certain patients with previously untreated CLL/SLL INDIANAPOLIS, Oct. 2, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved an additional indication for Jaypirca (pirtobrutinib, 100 mg & 50 mg tablets), a non-covalent Bruton tyrosine kinase (BTK) inhibitor, for the treatment of adult patients with previously untreated chronic lymphocytic leukemia or small lymphocytic lymph…

  View source ↗
• Newszacks.com·3d ago·Negative

  LLY Highlights New Efficacy Data From Foundayo and EloraTZP Studies Eli Lilly's new data show Foundayo's cardiovascular safety and metabolic benefits, while EloraTZP delivers greater weight loss and A1C reduction in a mid-stage study.

  View source ↗
• News247wallst.com·4d ago·Negative

  Prediction: Eli Lilly Could Be the Next $2 Trillion Drugmaker Eli Lilly just posted a 47.7% revenue surge while rivals like Novo Nordisk are watching earnings fall, and a fresh pipeline catalyst could push Lilly toward a valuation Wall Street has only seen from two companies in history.

  View source ↗
• News (RSS)fool·4d ago·Negative

  Johnson & Johnson vs. Eli Lilly: Which Pharma Stock Can Make Your Portfolio Healthier in 2026? JNJ trades at a 28% discount on valuation while LLY's cardiometabolic drugs drive 82% of revenue, each bet carries distinct growth and concentration risks.

  View source ↗
• 4chan /biz/biz·4d ago·Neutral

  >>62743830 PEP earnings October 8th will prove that reports of LLY's victory have been exaggerated

  View source ↗
• Newszacks.com·4d ago·Neutral

  Will Lilly (LLY) Beat Estimates Again in Its Next Earnings Report? Lilly (LLY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

  View source ↗
• News (Marketaux)seekingalpha.com·5d ago·Neutral

  Eli Lilly and Company (LLY) Presents at 2026 EASD Annual Meeting - Slideshow (NYSE:LLY) 2026-09-30 Eli Lilly and Company (LLY) Presents at 2026 EASD Annual Meeting - Slideshow (NYSE:LLY) 2026-09-30

  View source ↗
• Newszacks.com·5d ago·Neutral

  Eli Lilly (LLY) Suffers a Larger Drop Than the General Market: Key Insights In the most recent trading session, Eli Lilly (LLY) closed at $1, indicating a -2.33% shift from the previous trading day.

  View source ↗
• Newswsj.com·5d ago·Negative

  A next-generation weight-loss drug from Eli Lilly, when combined with Zepbound, helped people lose substantially more weight than Zepbound alone, according to a new study A drug combination studied in people with Type 2 diabetes lowered blood sugar and helped people lose more weight than with Zepbound alone.

  View source ↗
• Newsprnewswire.com·6d ago·Negative

  …ated with EBGLYSS reported being satisfied or very satisfied with hand clearance at Week 16 INDIANAPOLIS, Sept. 30, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that EBGLYSS (lebrikizumab-lbkz) monotherapy met its primary and secondary endpoints at Week 16 in the Phase 3b ADtouch study, showing significant and rapid improvements in hand and foot skin clearance, itch and pain in adults and adolescents with moderate-to-severe hand and foot atopic dermatitis (AD).

  View source ↗
• Newsfool.com·6d ago·Neutral

  Eli Lilly Might Be the Next Stock I Buy Eli Lilly (LLY -0.01%) continues to gain market share in the weight loss industry.

  View source ↗
• Newsfool.com·6d ago·Positive

  Opinion: Eli Lilly Stock Is a No-Brainer Pick to Buy on the Dip Lilly's pipeline is packed with metabolic health programs. Its commercialized metabolic health medicines are big earners.

  View source ↗
• Newsreuters.com·6d ago·Negative

  Lilly's experimental drug cuts weight by 21% in diabetes trial Eli Lilly ​said on ‌Tuesday its ​experimental ​drug helped adults ⁠with ​type 2 ​diabetes and obesity lose ​an ​average of nearly ‌21% ⁠of their body ​weight ​in ⁠a late-stage ​clinical ​trial.

  View source ↗
• News247wallst.com·6d ago·Negative

  Prediction: Eli Lilly's Next Growth Wave Could Surprise Investors Eli Lilly is growing faster than any other mega-cap drugmaker, but a pipeline drug still awaiting approval and falling U.S. prices are pulling the stock in opposite directions.

  View source ↗
• News (Marketaux)gurufocus.com·6d ago·Positive

  Eli Lilly's Foundayo Shows Superior Weight Loss Results; LLY Stock Modestly Undervalued On September 29, 2026, Eli [+278 characters]

  View source ↗
• Newsseekingalpha.com·7d ago·Positive

  Wall Street Breakfast Podcast: Federal Boost For Navitas Navitas Semiconductor (NVTS) surged 12% premarket after winning a U.S. Army contract to develop next-gen silicon carbide power semiconductor technology. Eli Lilly (LLY) signals intent for larger, earlier-stage acquisitions in infectious disease, women's health, and mental health to drive future growth.

  View source ↗
• Newsprnewswire.com·7d ago·Negative

  …yo 9 mg and 17.2 mg delivered greater A1C and weight reductions than oral semaglutide 14 mg INDIANAPOLIS, Sept. 29, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide), today announced results from a new analysis showing that Foundayo (orforglipron) 17.2 mg was associated with significantly greater weight loss and better blood sugar control than oral semaglutide 25 mg in adults with type 2 diabetes.

  View source ↗
• Newszacks.com·7d ago·Neutral

  LLY's Olumiant Gets FDA Nod for Expanded Use in Pediatric Hair Loss Eli Lilly's Olumiant wins FDA nod to treat pediatric patients 12 years of age and older with severe alopecia areata, expanding its U.S. use after strong phase III results.

  View source ↗
• Newszacks.com·7d ago·Positive

  Eli Lilly (LLY) is a Top-Ranked Momentum Stock: Should You Buy? The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

  View source ↗
• Newszacks.com·7d ago·Neutral

  Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.

  View source ↗
• Newsprnewswire.com·8d ago·Neutral

  Lilly launches the Lilly Change the Course Commitment, aiming to address treatment gaps in diabetes and obesity in LMICs Through this commitment, Lilly aims to expand access to its innovative diabetes and obesity medicines to as many people in resource-limited settings, including low- and middle-income countries (LMICs), as in high-income countries, before 2040 Key highlights: Lilly today launched the Lilly Change the Course Commitment , a new global health initiative with a simple, yet ambitiou

  View source ↗
• Newsfool.com·8d ago·Negative

  Eli Lilly Just Announced Game-Changing News The weight loss drug market has reached an important turning point. Eli Lilly is the leader in this market, but faces strong competition from Novo Nordisk.

  View source ↗
• News247wallst.com·8d ago·Negative

  Eli Lilly Just Won FDA Approval for a Once Weekly Insulin and the Stock Is Knocking on $1,200 The FDA just handed Eli Lilly a new diabetes approval, but the real debate is whether a once-weekly insulin needle moves the needle on a stock already up 60% and closing in on record highs.

  View source ↗
• 4chan /biz/biz·8d ago·Positive

  >>62730303 Buy LLY

  View source ↗
• 4chan /biz/biz·9d ago·Positive

  >>62728604 I'm only swing trading MU, which is bad in the long run but I've still managed to secure some gains. Everything semis is retardedly expensive atm, I think looking at SNDK's price is a good market indicator, like if it's above 1400, it's too expensive to buy. You can get into some safer stuff like AAPL, LLY or JPM and wait for a 10-20% correction similar to July.

  View source ↗
• Newsprnewswire.com·10d ago·Negative

  …s Severe AA can result in extensive hair loss during adolescence, a formative stage of life INDIANAPOLIS, Sept. 25, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) approved Olumiant (baricitinib), a once-daily pill, for the treatment of pediatric patients 12 years of age and older with severe alopecia areata (AA).1 The approval expands Olumiant's U.S. label, building on its established use in adults with moderately to severe…

  View source ↗
• Newszacks.com·10d ago·Neutral

  LLY's Onswik Wins FDA Nod as a Once-Weekly Basal Insulin for T2D Eli Lilly gets FDA approval for once-weekly Onswik, offering adults with type II diabetes a more convenient alternative to daily basal insulin.

  View source ↗
• Newszacks.com·10d ago·Positive

  Why Eli Lilly (LLY) is a Top Growth Stock for the Long-Term Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

  View source ↗
• Newsseekingalpha.com·11d ago·Positive

  TRex Bio Files For IPO As Collaboration With Eli Lilly Deepens TRex Bio is a clinical-stage biopharma targeting autoimmune and inflammatory diseases, with a lead program in Phase 1b trials for treating atopic dermatitis. TRXB's deepening collaboration with Eli Lilly, including milestone payments and potential IPO participation, signals strong strategic backing and validation. The company is well-capitalized, with a high-quality and diverse investor syndicate, but will require further funding bey

  View source ↗
• 4chan /biz/biz·11d ago·Neutral

  >LLY<3

  View source ↗
• Newsnypost.com·11d ago·Negative

  FDA approves Eli Lilly's once-weekly insulin injection for type 2 diabetes The once-weekly ​treatment could reduce the number of injections by more ⁠than 300 per year compared with once-daily basal insulin, ​Eli Lilly said.

  View source ↗
• News (Marketaux)gurufocus.com·11d ago·Positive

  LLY Looks 26.0% Undervalued on GF Value™ After FDA Approval of Onswik On September 24, 2026, Eli [+327 characters]

  View source ↗
• Newsreuters.com·12d ago·Negative

  US FDA approves Lilly's once-weekly insulin injection for type 2 diabetes The US Food and Drug Administration has approved Eli Lilly's once-weekly basal insulin, Onswik, for adults with type ​2 diabetes, the drugmaker said on Thursday, offering patients ‌an alternative to daily long-acting insulin injections.

  View source ↗
• Newsinvezz.com·13d ago·Negative

  Novo wants to change how Wall Street owns its stock: why now Novo Nordisk wants a bigger presence on Wall Street, and the timing may say more about the drugmaker's challenges than the listing itself. Chief executive Mike Doustdar said Novo could see advantages in replacing its American depositary receipts with shares listed directly in New York.

  View source ↗
• 4chan /biz/biz·13d ago·Positive

  >>62717515 The hilarious part is some boomer on CNBC was pumping LLY today, claiming it’s an easy hit to $2,000 in 3 to 4 years. Then LLY immediately drops -2% at market open because investors think a multi-bagger pharma play is too slow compared to AI hyper-growth.

  View source ↗
• 4chan /biz/biz·13d ago·Neutral

  >>62717141 LLY runs up every once in awhile, or down every once in awhile but it keeps returning to the mean of XBI

  View source ↗
• 4chan /biz/biz·13d ago·Neutral

  Did you ever notice how closely LLY moves with XBI? There's something going on here. It can't just be a coincidence.

  View source ↗
• News (Marketaux)finance.yahoo.com·13d ago·Positive

  Should Dividend Investors Buy Pfizer Stock for Its High Yield or Invest in Eli Lilly for Its Dividend Growth? Two intriguing dividend stocks that can [+318 characters]

  View source ↗
• Newsbenzinga.com·13d ago·Negative

  Eli Lilly Gets Full FDA Approval for Inluriyo in ESR1-Mutated Breast Cancer The U.S. Food and Drug Administration (FDA) on Friday granted full approval to Eli Lilly and Co.'s (NYSE:LLY) Inluriyo (imlunestrant) in combination with Verzenio (abemaciclib) for pretreated breast cancer patients.

  View source ↗
• Newszacks.com·13d ago·Negative

  Novo's CagriSema Outshines Zepbound in Key Phase III Weight-Loss Study NVO's CagriSema delivers greater weight loss than Eli Lilly's tirzepatide in T2D and 21% weight loss in obesity, strengthening its late-stage pipeline.

  View source ↗
• News247wallst.com·13d ago·Negative

  His Bet On Home Depot Made Ken Langone A Billionaire. Now He Sees Eli Lilly Stock Hitting $2,000 Ken Langone, chairman and president of Invemed Associates and a co-founder of Home Depot (NYSE:HD | HD Price Prediction), used a CNBC Squawk Box appearance on September 22, 2026 to say that his Eli Lilly (NYSE:LLY) position is now pushing

  View source ↗
• Newszacks.com·14d ago·Neutral

  Eli Lilly (LLY) Increases Yet Falls Behind Market: What Investors Need to Know Eli Lilly (LLY) closed at $1 in the latest trading session, marking a +1.04% move from the prior day.

  View source ↗
• News (Marketaux)gurufocus.com·14d ago·Positive

  LLY Looks 25.1% Undervalued on GF Value™ as Oral GLP-1 Gains Traction On September 21, 2026, Eli [+344 characters]

  View source ↗
• Newsprnewswire.com·14d ago·Negative

  … million in support to build talent pipeline, workforce training center with San Jacinto College HOUSTON, Sept. 21, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) broke ground today in Houston, Texas, one of ten U.S. manufacturing sites — and fifth location to produce domestic active pharmaceutical ingredients (API) — announced since 2020.

  View source ↗
• News247wallst.com·14d ago·Neutral

  The Next Chapter of Eli Lilly Could Be Bigger Than Investors Expect Eli Lilly is posting 48% revenue growth while its stock sits nearly flat for the year, and that disconnect points to something Wall Street may be mispricing entirely.

  View source ↗
• News247wallst.com·14d ago·Negative

  Nvidia vs. Eli Lilly: I'd Choose This Stock for the Next Decade NVIDIA and Eli Lilly both shattered expectations this quarter, but picking the better stock for the next decade means choosing between two very different growth machines at very different levels of risk.

  View source ↗
• News (Marketaux)gurufocus.com·16d ago·Neutral

  LLY Looks 25.3% Undervalued on GF Value™ Amid Legal Concerns On September 19, 2026, Eli [+255 characters]

  View source ↗
• Newsreuters.com·17d ago·Negative

  US FDA approves Lilly's breast cancer drug combo The US FDA has approved Eli Lilly's drug combination to treat adults with a type of advanced breast cancer that ​has spread to other parts of the body, the drugmaker ‌said on Friday.

  View source ↗
• Newsprnewswire.com·17d ago·Negative

  …ER+ breast cancer, with an established tolerability profile and no new monitoring required  INDIANAPOLIS, Sept. 18, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has granted full approval to Inluriyo (imlunestrant), an oral estrogen receptor (ER) antagonist, in combination with Verzenio (abemaciclib), a CDK4/6 inhibitor, for the treatment of adults with estrogen receptor-positive (ER+), human epidermal growth factor recept…

  View source ↗
• Newsfool.com·19d ago·Negative

  This Trend is Excellent News for Eli Lilly and Its Investors Eli Lilly dominates the weight loss drug market -- one set to approach $100 billion in a few years. Lilly and rival Novo Nordisk launched weight loss pills this year, and so far, Novo is leading in prescriptions.

  View source ↗
• Newszacks.com·19d ago·Neutral

  Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

  View source ↗
• News (RSS)zerohedge·20d ago·Neutral

  …Buster’s (PLAY) drops 13% after the restaurant and arcade chain operator reported revenue for the second quarter that missed the average analyst estimate. Eli Lilly (LLY) is up 1.3% after Berenberg upgraded the pharmaceutical giant, with analysts arguing it’s worthy of a more significant valuation premium due to its superior growth profile and the breadth of its pipeline. Enova International (ENVA) falls 18% after the financial services company withdrew its applications with the Office of the Co…

  View source ↗
• News247wallst.com·21d ago·Positive

  There Are Plenty of Eli Lilly Bulls: Here's What They Aren't Telling You Eli Lilly's bulls are pointing at a 47% revenue surge and a pipeline loaded with blockbuster candidates, but there are a few uncomfortable details quietly buried in the earnings report that change how the story reads.

  View source ↗
• News247wallst.com·21d ago·Neutral

  Eli Lilly Vs. Merck: One is a No-Brainer to Hold Through 2030 Eli Lilly and Merck both reported second quarter earnings, and the contrast could not be sharper. One company is compounding a franchise that keeps widening, while the other is racing to patch a hole before a patent cliff arrives.

  View source ↗
• Newszacks.com·21d ago·Neutral

  Why the Market Dipped But Eli Lilly (LLY) Gained Today Eli Lilly (LLY) concluded the recent trading session at $1, signifying a +1.99% move from its prior day's close.

  View source ↗
• Newsseekingalpha.com·21d ago·Positive

  Eli Lilly and Company (LLY) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Eli Lilly and Company (LLY) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

  View source ↗
• Newsreuters.com·21d ago·Negative

  Lilly says Foundayo has captured over 30% of new US patients on oral weight-loss drugs Eli Lilly on Monday said it has captured more than 30% of new patients in the U.S. market for oral obesity ​treatments, narrowing the early lead gained by Danish rival Novo Nordisk ‌with its Wegovy pill.

  View source ↗
• Newsmarketbeat.com·21d ago·Neutral

  Eli Lilly Eyes Obesity Access Expansion With Zepbound, Foundayo and Pipeline Bets Eli Lilly and Company NYSE: LLY is pursuing a broad obesity portfolio designed to address different patient needs across treatment initiation, maintenance, efficacy, tolerability and dosing convenience, according to Ilya Yuffa, the company's executive vice president and president of Lilly USA and Global Customer Capabilities.

  View source ↗
• News247wallst.com·22d ago·Neutral

  Eli Lilly Fell Like a Rock Over the Last Month: This Big Bank Expects 45% Returns Over The Next Twelve Eli Lilly shed billions in market value over the past month while its underlying business kept breaking records, and now one major Wall Street firm sees a setup that almost never appears in a stock this dominant.

  View source ↗
• Newswsj.com·22d ago·Negative

  People are taking bootleg versions of an Eli Lilly drug that isn't approved yet. Ohio wants it to stop. As bootleg versions of an experimental drug from Eli Lilly flood the market, regulators are trying to curb supply.

  View source ↗
• 4chan /biz/biz·22d ago·Positive

  >>62685472 I'm buying back into NVO after taking profit some months ago. Can't tell you the near future but there's no reason for it to be this low when you compare P/E to LLY. Just the divvie alone is good enough for me, let it crab. Also starting to slurp some UBER and NKE Buying more of NFLX

  View source ↗
• News (RSS)yahoo·23d ago·Neutral

  Eli Lilly’s (LLY) GLP-1 Growth Made It a Core “Running Back” Stock for Jim Cramer

  View source ↗
• Newsprnewswire.com·25d ago·Neutral

  … to advance therapies for treatment-resistant depression and other mental health conditions INDIANAPOLIS, Sept. 11, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of AtaiBeckley Inc. AtaiBeckley is a clinical-stage biopharmaceutical company developing rapid-acting neuroplastogens for mental health conditions, including BPL-003, its lead investigational program for treatment-resistant depression.

  View source ↗
• News247wallst.com·25d ago·Neutral

  Got $10,000? Eli Lilly vs. Eli Lilly and Nvidia both just posted stunning quarters riding two of the biggest secular waves in markets today, but a $10,000 bet can only tilt one way. Which secular story holds the sharper edge heading into 2026?

  View source ↗
• News (RSS)yahoo·26d ago·Neutral

  Jim Cramer Picks J&J (JNJ) Over Eli Lilly (LLY) and Pfizer (PFE) Among These Healthcare Stocks

  View source ↗
• Newszacks.com·27d ago·Neutral

  Here's Why Eli Lilly (LLY) Fell More Than Broader Market The latest trading day saw Eli Lilly (LLY) settling at $1, representing a -2.21% change from its previous close.

  View source ↗
• Newszacks.com·27d ago·Neutral

  Wall Street Bulls Look Optimistic About Lilly (LLY): Should You Buy? The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.

  View source ↗
• 4chan /biz/biz·28d ago·Neutral

  >>62669467 Pick 8 giga compounders. I made it diversified for you. GOOGL AMZN NVDA LLY AVGO GE KO TJX

  View source ↗
• Newszacks.com·28d ago·Positive

  Here's Why Eli Lilly (LLY) is a Strong Growth Stock Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

  View source ↗
• 4chan /biz/biz·30d ago·Neutral

  I decided that I'm going to give you guys a portfolio of big compounders, safe ones that you can put all your money into. I'm serious. I'd be comfortable cutting this list in half and putting all my money into 5 of these. to go with my post here >>62664262 GOOGL NVDA AMZN LLY AMP AVGO TJX AMAT GE KO (or BRKB) You will be safe if you just all in one this portfolio. Just equal weight them. They will be a compounding machine that grinds up in most regimes.

  View source ↗
• Newsfool.com·30d ago·Neutral

  Here's Why Billionaires Stanley Druckenmiller and Ken Griffin Are Loading Up on Eli Lilly Stock Griffin's Citadel Advisors and Druckenmiller's Duquesne Family Office bought Lilly stock in Q2. The billionaires likely capitalized on an opportunity with Lilly's shares tumbling early in the quarter.

  View source ↗
• Newsfool.com·30d ago·Positive

  Will Eli Lilly Split Its Stock? Here's What History Says Will Happen If It Does. Eli Lilly hasn't split its stock in nearly 30 years, but as shares trade above $1,000, the pharmaceutical company could be considering one. Considering other high-profile stock splits in recent years, count on company-specific catalysts, not the split itself, to drive further gains.

  View source ↗
• News (Marketaux)insidermonkey.com·31d ago·Positive

  Lilly Launches Foundayo in the UK as NICE Review Continues Eli Lilly and[+217 characters]

  View source ↗
• News (Marketaux)insidermonkey.com·31d ago·Positive

  Could Roche and Lilly’s Blood Test Make Alzheimer’s Assessment More Accessible? Roche Holding AG and Eli Li[+351 characters]

  View source ↗
• 4chan /biz/biz·31d ago·Positive

  …g moats generally, so be aware you're looking for companies with strong moat. Here's you an example equal weight portfolio to demonstrate NVDA AVGO GOOGL META BKNG LLY COST GWW V

  View source ↗
• Newsfool.com·32d ago·Neutral

  Great News for Eli Lilly Stock Investors Eli Lilly's tirzepatide is showing potential across autoimmune diseases. The medicine could earn additional indications and attract broader insurance coverage over time.

  View source ↗
• News247wallst.com·33d ago·Negative

  Lilly's Record Stock Price Is Hiding an Even Bigger Opportunity Eli Lilly just delivered one of the biggest quarters in Big Pharma history, yet the stock sits well below its 52-week high. A closer look at the pipeline and valuation reveals why the real opportunity may still be ahead.

  View source ↗
• Newszacks.com·33d ago·Positive

  Here's Why Eli Lilly (LLY) is a Strong Momentum Stock The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

  View source ↗
• Newsfool.com·34d ago·Neutral

  This New Zepbound Study Could Be Great News for Eli Lilly Investors The results of a study Eli Lilly ran suggest that patients older than 55 on Zepbound incur lower healthcare costs than those not on Zepbound. This could help the company make the case for expanded Zepbound coverage.

  View source ↗
• Newszacks.com·34d ago·Positive

  Eli Lilly to Buy Immunology Biotech Merida Biosciences in $2.9B Deal LLY's $2.9B Merida deal adds immunology assets and expands its pipeline beyond obesity and diabetes into new growth areas.

  View source ↗
• News (RSS)yahoo·35d ago·Neutral

  Eli Lilly (LLY) Makes a $2.88 Billion Autoimmune Bet. What Could Go Right or Wrong?

  View source ↗
• News (Marketaux)gurufocus.com·35d ago·Positive

  LLY Looks 24.4% Undervalued on GF Value™ Amid Obesity Treatment Market Surge Eli Lilly and[+341 characters]

  View source ↗
• Newsfool.com·35d ago·Neutral

  Eli Lilly Is Acquiring Merdia Biosciences for Up to $2.88 Billion. Here's What That Means for Investors. It has agreed to pay up to nearly $2.88 billion for a clinical-stage biotech. That company's uniqueness was a clear attraction for the pharmaceutical giant.

  View source ↗
• Newsproactiveinvestors.com·35d ago·Positive

  Eli Lilly to buy Merida Biosciences for up to $2.88B, expanding immunology pipeline Eli Lilly and Co (NYSE:LLY) said on Monday it will acquire privately held Merida Biosciences for up to $2.88 billion in cash, part of a deal-making push to broaden its treatments for immune-related and allergic diseases. The acquisition continues a run of dealmaking for Lilly, whose deal spending this year has outpaced prior years as it looks to diversify beyond its blockbuster obesity and diabetes franchises.

  View source ↗
• Newszacks.com·35d ago·Negative

  LLY's Mounjaro Gets FDA Nod to Cut Cardiovascular Risk in Diabetes Eli Lilly's Mounjaro wins FDA approval to reduce cardiovascular risk in high-risk T2D patients, expanding its use and commercial opportunity.

  View source ↗
• Newsbarrons.com·36d ago·Negative

  Lilly to Buy This Autoimmune Drugmaker for $2.9 Billion in Cash. What It Means for the Stock. Eli Lilly agrees to acquire Merida Biosciences, the developer of autoimmune drugs, marking the latest move to bolster its portfolio through strategic acquisitions.

  View source ↗
• Newswsj.com·36d ago·Negative

  Eli Lilly to Buy Merida Biosciences For Up to $2.875 Billion Eli Lilly has agreed to pay up to $2.875 billion in cash for biotechnology company Merida Biosciences in a deal that bolsters the drugmaker's immunology portfolio.

  View source ↗
• Newsprnewswire.com·36d ago·Negative

  …a from first-of-their-kind studies contribute to the understanding of immunometabolic health INDIANAPOLIS, Aug. 31, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced 52-week results from TOGETHER-PsO and TOGETHER-PsA, two novel open-label Phase 3b clinical trials evaluating the concomitant use of Taltz (ixekizumab) and Zepbound (tirzepatide) compared to Taltz alone in adults with moderate-to-severe plaque psoriasis (PsO) or active psoriatic arthritis (PsA), respectively, and…

  View source ↗
• Newsprnewswire.com·36d ago·Neutral

  …e standard of care for immune-mediated conditions with high unmet need  INDIANAPOLIS and CAMBRIDGE, Mass., Aug. 31, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Merida Biosciences, Inc. (Merida), a biotechnology company advancing a new class of precision therapeutics for serious autoimmune and allergic diseases, today announced a definitive agreement for Lilly to acquire Merida.

  View source ↗
• News (Marketaux)gurufocus.com·38d ago·Neutral

  LLY Looks 22.7% Undervalued on GF Value™ After FDA Approval Boost On August 28, 2026, Eli Lil[+252 characters]

  View source ↗
• Newsreuters.com·39d ago·Negative

  US FDA approves Lilly's Mounjaro to reduce cardiovascular risk Eli Lilly ​said on ‌Friday the U.S. ​FDA ​has approved its ⁠diabetes drug ​Mounjaro ​to lower the risk of ​major ​adverse cardiovascular events ‌in ⁠adults with type 2 ​diabetes ​who ⁠are at ​high ​risk ⁠for these events.

  View source ↗
• Newsbenzinga.com·40d ago·Negative

  Eli Lilly Stock Pulls Back After Hitting Record Highs Last Week Eli Lilly and Co. (NYSE:LLY) shares are trading lower Wednesday, pulling back after the stock notched an all-time high just last week, even as the company separately reported positive real-world data on its weight-loss drug Zepbound. Here's what you should know.

  View source ↗
• Newszacks.com·41d ago·Negative

  LLY vs. ABBV: Which Stock Has the Stronger Growth Prospects? Lilly and AbbVie bring different growth drivers, pipelines and risks to the table. See which drugmaker offers the more compelling 2026 upside.

  View source ↗
• News247wallst.com·42d ago·Negative

  Eli Lilly Has a $100 Billion Revenue Story in the Making Eli Lilly (NYSE:LLY | LLY Price Prediction) is trading at $1,255.40, and management has guided fiscal 2026 revenue between $85 billion and $87 billion.

  View source ↗
• Newswsj.com·43d ago·Negative

  Eli Lilly Launches Foundayo Weight-Loss Pill in U.K. The once-daily pill was approved for patients with a body mass index of at least 30, or between 27 and 30 in the event of at least one weight-related health condition.

  View source ↗